JP2018503649A5 - - Google Patents

Download PDF

Info

Publication number
JP2018503649A5
JP2018503649A5 JP2017539596A JP2017539596A JP2018503649A5 JP 2018503649 A5 JP2018503649 A5 JP 2018503649A5 JP 2017539596 A JP2017539596 A JP 2017539596A JP 2017539596 A JP2017539596 A JP 2017539596A JP 2018503649 A5 JP2018503649 A5 JP 2018503649A5
Authority
JP
Japan
Prior art keywords
crystalline
composition
compound
pyrrole
chlorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017539596A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018503649A (ja
JP7258460B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/015829 external-priority patent/WO2016123574A1/en
Publication of JP2018503649A publication Critical patent/JP2018503649A/ja
Publication of JP2018503649A5 publication Critical patent/JP2018503649A5/ja
Application granted granted Critical
Publication of JP7258460B2 publication Critical patent/JP7258460B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017539596A 2015-01-30 2016-01-29 C21H22Cl2N4O2の結晶形態 Active JP7258460B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562110449P 2015-01-30 2015-01-30
US62/110,449 2015-01-30
PCT/US2016/015829 WO2016123574A1 (en) 2015-01-30 2016-01-29 Crystalline forms of c21h22ci2n4o2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020063198A Division JP2020100674A (ja) 2015-01-30 2020-03-31 C21H22Cl2N4O2の結晶形態

Publications (3)

Publication Number Publication Date
JP2018503649A JP2018503649A (ja) 2018-02-08
JP2018503649A5 true JP2018503649A5 (https=) 2019-02-14
JP7258460B2 JP7258460B2 (ja) 2023-04-17

Family

ID=56544441

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2017539596A Active JP7258460B2 (ja) 2015-01-30 2016-01-29 C21H22Cl2N4O2の結晶形態
JP2020063198A Pending JP2020100674A (ja) 2015-01-30 2020-03-31 C21H22Cl2N4O2の結晶形態
JP2021195403A Pending JP2022033866A (ja) 2015-01-30 2021-12-01 C21H22Cl2N4O2の結晶形態
JP2023081553A Withdrawn JP2023096080A (ja) 2015-01-30 2023-05-17 C21H22Cl2N4O2の結晶形態
JP2025050047A Pending JP2025089464A (ja) 2015-01-30 2025-03-25 C21H22Cl2N4O2の結晶形態

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020063198A Pending JP2020100674A (ja) 2015-01-30 2020-03-31 C21H22Cl2N4O2の結晶形態
JP2021195403A Pending JP2022033866A (ja) 2015-01-30 2021-12-01 C21H22Cl2N4O2の結晶形態
JP2023081553A Withdrawn JP2023096080A (ja) 2015-01-30 2023-05-17 C21H22Cl2N4O2の結晶形態
JP2025050047A Pending JP2025089464A (ja) 2015-01-30 2025-03-25 C21H22Cl2N4O2の結晶形態

Country Status (12)

Country Link
US (6) US9676746B2 (https=)
EP (2) EP4477222A3 (https=)
JP (5) JP7258460B2 (https=)
CN (2) CN107406413A (https=)
AU (5) AU2016211246B2 (https=)
CA (2) CA2975048C (https=)
ES (1) ES3009552T3 (https=)
HK (1) HK1244274A1 (https=)
MX (1) MX382289B (https=)
NZ (2) NZ734041A (https=)
SG (2) SG11201705924RA (https=)
WO (1) WO2016123574A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095842A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
AU2016211246B2 (en) * 2015-01-30 2020-08-27 Biomed Valley Discoveries, Inc. Crystalline forms of C21H22CI2N4O2
CA3008701A1 (en) * 2016-01-27 2017-08-03 Jiangsu Hengrui Medicine Co., Ltd. Method for preparing pharmaceutical composition comprising quinoline derivative or salt thereof
WO2021020841A1 (en) * 2019-07-29 2021-02-04 Standigm Inc. Composition for preventing or treating metabolic liver disease
WO2021102279A1 (en) * 2019-11-20 2021-05-27 University Of Kentucky Research Foundation Anti-cancer compositions and methods
CN118765276A (zh) * 2022-03-08 2024-10-11 甘李药业股份有限公司 氘代化合物,及其制备方法和应用
IL315702A (en) * 2022-03-24 2024-11-01 Biomed Valley Discoveries Inc Deuterated pyrrole inhibitory analogs of ERK, their synthesis and their intermediates

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599331A (en) 1984-12-24 1986-07-08 Syntex (U.S.A.) Inc. Etianic acids as antiangiogenics
JP2545522B2 (ja) 1985-10-23 1996-10-23 アルコン・ラボラトーリーズ,インコーポレイテッド テトラヒドロ脈管形成抑制ステロイド
US4771042A (en) 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
EP0477195A1 (en) 1989-06-16 1992-04-01 The Upjohn Company Suramin type compounds and angiostatic steroids to inhibit angiogenesis
WO1993010141A2 (en) 1991-11-22 1993-05-27 Alcon Laboratories, Inc. Angiostatic steroids
HUP0202332A2 (en) 2000-02-05 2002-10-28 Vertex Pharma Pyrazole compositions useful as inhibitors of erk
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
AU2003237121A1 (en) * 2002-04-26 2003-11-10 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
LT3305776T (lt) 2004-05-14 2020-01-10 Vertex Pharmaceuticals Incorporated Pirolo junginiai kaip erk baltymo kinazės inhibitoriai, ir farmacinės kompozicijos su šiais junginiais
US7582623B2 (en) 2004-05-20 2009-09-01 The Regents Of The University Of California Photoactive metal nitrosyls for blood pressure regulation and cancer therapy
KR101125932B1 (ko) 2006-12-06 2012-03-22 아이디유엔 파마슈티칼즈, 인코포레이티드 (3s)-3-[n-(n'-(2-tert-부틸페닐)옥사밀)알라니닐]아미노-5-(2',3',5',6'-테트라플루오로페녹시)-4-옥소펜탄산의 결정 형태
CN104684555A (zh) * 2012-09-18 2015-06-03 奥斯拜客斯制药有限公司 囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学
US9227969B2 (en) * 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
AU2016211246B2 (en) * 2015-01-30 2020-08-27 Biomed Valley Discoveries, Inc. Crystalline forms of C21H22CI2N4O2

Similar Documents

Publication Publication Date Title
JP2018503649A5 (https=)
JP2015512942A5 (https=)
JP2019517487A5 (https=)
JP2013522232A5 (https=)
JP2014506907A5 (https=)
JP2018531280A5 (https=)
JP2014516360A5 (https=)
BRPI0813625A2 (pt) Imidazo-[1,2b]-piridozinas 2,3,7-substituídos para tratamento de doenças mediadas por alzk4 ou alk5
JP2016522266A5 (https=)
JP2014526469A5 (https=)
JP2015501799A5 (https=)
JP2012533570A5 (https=)
JP2010538001A5 (https=)
JP2014507455A5 (https=)
MX2008013212A (es) 4-anilinquinolina-3-carboxamidas como inhibidores de la cinsa csf-1r.
PH12016501651A1 (en) Triazine compound and use thereof for medical purposes
RU2015103065A (ru) Кристаллическая форма i дималеата ингибитора тирозинкиназы и способ ее получения
JP2018534288A5 (https=)
JP2014534269A5 (https=)
CA2447765A1 (en) 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors
WO2016004404A3 (en) Gls1 inhibitors for treating disease
WO2014011971A3 (en) Deuterated carfilzomib
RU2017134709A (ru) П-толуолсульфонат для ингибитора мек-киназы и его кристаллическая форма, и способ его получения
EP4477222A3 (en) Crystalline 4-(5-chloro-2-isopropylaminopyridin-4-yl)-1h-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide hydrochloride salt
WO2016051306A3 (en) Novel anthranilic acid derivatives